Apatinib, a small-molecule tyrosine kinase inhibitor, selectively binds to vascular endothelial growth factor receptor 2 (VEGFR-2), strongly inhibiting its activity and reducing VEGF-mediated endothelial cell migration, proliferation, and tumor microvessel density (67). Here, KDR is linked to neoplasm.